Improving Scientific Rigor of Renal Clinical Endpoints for Sickle Cell Anemia

Launched by UNIVERSITY OF ALABAMA AT BIRMINGHAM · May 5, 2020

Keywords

ClinConnect Summary

This clinical trial, titled "Improving Scientific Rigor of Renal Clinical Endpoints for Sickle Cell Anemia," is focused on developing a better way to estimate kidney function in patients with sickle cell disease. The researchers want to create a new equation that can accurately calculate something called estimated Glomerular Filtration Rate (eGFR), which helps doctors understand how well the kidneys are working. This study will include both children and adults, specifically those aged between 5 and 50 who have sickle cell anemia.

If you or a loved one has sickle cell disease and fits the age criteria, you may be eligible to participate in this trial. However, individuals who have had recent serious complications related to sickle cell anemia, or specific kidney issues, will not be included. Participants will be monitored throughout the study, and their health will be closely observed to ensure safety. This research aims to improve the understanding of kidney health in sickle cell patients, which is important for better treatment and care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • SCA patients (HbSS and SB0 thalassemia)
• • Age: 5.0-50.0 at enrollment
• Exclusion Criteria:
• • Recent SCA complication associated with hospitalization (within 30 days) or ED visit (within 14 days)
• • Current AKI defined as \>0.3mg/g increase in SCr from prior visit
• • Known history of anaphylaxis with contrast agent or known pregnancy